Luca Stingeni

Perugia, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 273 publications

Clinical profile, patient experience, and management of vitiligo in Italy: Data from the National 2024 Vitiligo Week Awareness Campaign.

Clinical profile, patient experience, and management of vitiligo in Italy: Data from the National 2024 Vitiligo Week Awareness Campaign.

Journal: JAAD international

Published: August 01, 2026

Real-world effectiveness of topical ruxolitinib in non-segmental vitiligo: repigmentation, mental health, and quality-of-life outcomes in an 860-patient multicentre study.

Real-world effectiveness of topical ruxolitinib in non-segmental vitiligo: repigmentation, mental health, and quality-of-life outcomes in an 860-patient multicentre study.

Journal: The British journal of dermatology

Published: May 16, 2026

Real-Life Effectiveness, Safety, and Growth Outcomes of Dupilumab in Children Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis: A Multicenter Retrospective Study from an Italian NPP Program.

Real-Life Effectiveness, Safety, and Growth Outcomes of Dupilumab in Children Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis: A Multicenter Retrospective Study from an Italian NPP Program.

Journal: Dermatitis : contact, atopic, occupational, drug

Published: May 07, 2026

The Importance of Achieving High Treatment Targets in Atopic Dermatitis: A Narrative Review.

The Importance of Achieving High Treatment Targets in Atopic Dermatitis: A Narrative Review.

Journal: Dermatology and therapy

Published: March 13, 2026

Treatment Outcomes of Lebrikizumab after Switching from Dupilumab in Moderate-to-Severe Atopic Dermatitis involving the Head and Neck Area.

Treatment Outcomes of Lebrikizumab after Switching from Dupilumab in Moderate-to-Severe Atopic Dermatitis involving the Head and Neck Area.

Journal: Dermatology and therapy

Published: March 11, 2026

Patch Test Results With Additions to the European Baseline Series, 2021/22-Joint European Results of the ESSCAA and the EBSB Working Groups of the ESCD, and the GEIDACC.

Patch Test Results With Additions to the European Baseline Series, 2021/22-Joint European Results of the ESSCAA and the EBSB Working Groups of the ESCD, and the GEIDACC.

Journal: Contact dermatitis

Published: February 28, 2026

Patch Test Results With Additions to the European Baseline Series, 2021/22-Joint European Results of the ESSCAA and the EBSB Working Groups of the ESCD, and the GEIDACC.

Patch Test Results With Additions to the European Baseline Series, 2021/22-Joint European Results of the ESSCAA and the EBSB Working Groups of the ESCD, and the GEIDACC.

Journal: Contact dermatitis

Published: February 28, 2026

An Algorithm for the Diagnosis and Treatment of Allergic Contact Dermatitis (ACD).

An Algorithm for the Diagnosis and Treatment of Allergic Contact Dermatitis (ACD).

Journal: Allergy

Published: February 11, 2026

Effectiveness and Safety of IL-17A Inhibitors in Pediatric Psoriasis: A Real-World, Multicenter, International Study.

Effectiveness and Safety of IL-17A Inhibitors in Pediatric Psoriasis: A Real-World, Multicenter, International Study.

Journal: Paediatric drugs

Published: February 11, 2026

European Society of Contact Dermatitis Guideline for Diagnostic Patch Testing-Recommendations on Best Practice (Update 2026).

European Society of Contact Dermatitis Guideline for Diagnostic Patch Testing-Recommendations on Best Practice (Update 2026).

Journal: Contact dermatitis

Published: February 10, 2026

Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER study.

Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER study.

Journal: The Journal of dermatological treatment

Published: February 06, 2026

Incidence and risk factors of brain metastases in radically resected melanoma patients: a large international cohort study.

Incidence and risk factors of brain metastases in radically resected melanoma patients: a large international cohort study.

Journal: ESMO open

Published: December 10, 2025

Showing 1-12 of 273

Last Updated: 09/26/2026